In a BSE filing, Strides Shasun said: "It has received approval from the US Food and Drug Administration (USFDA) for Polyethylene Glycol 3350, powder for solution 17 grams/capful and 17 grams/packet (OTC)".
The company said it will manufacture the product at its Bangalore plant and launch the product in the fourth quarter of this fiscal.
Quoting IMS sales data, Strides Shasun said the US market for Polyethylene Glycol 3350, powder for solution is around USD 260 million.
Strides Shasun's shares were trading 0.88 per cent higher at Rs 973.50 apiece on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content